ReviewFrontiers in psychiatry2019
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy.
Review in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- A Systematic Review of the MDMA Model to Address Social Impairment in Autism.Current neuropharmacology · 2021Pooled it
- Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.Translational psychiatry · 2026Trial
- Evaluating the attitudes of mental health professionals towards trials of MDMA: a randomised vignette trial.BMJ open · 2022Trial
- Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use.Molecular psychiatry · 2026Review
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.Current issues in molecular biology · 2026Review
- Lifetime MDMA use and associations with meaning in life in the context of childhood trauma.Scientific reports · 2026Article
- Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study.Frontiers in psychology · 2026Article
- Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Exploring MDMA assisted therapy in eating disorders: mechanisms, clinical evidence, and future directions.Journal of eating disorders · 2025Review
- Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights.ACS chemical neuroscience · 2025Article
- Intermittent MDMA Attenuates Ovariectomy-induced Bone Loss via a Gut Microbiota-Bone Axis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.CNS spectrums · 2025Review
- A biopsychosocial model of MDMA-assisted therapy in application: Dyadic One Session Treatment for specific phobia.Frontiers in psychiatry · 2025Article
- Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach.Frontiers in psychiatry · 2025Article
- Effects of chronic stress on cognitive function - From neurobiology to intervention.Neurobiology of stress · 2024Review
- Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature.Pharmaceutics · 2024Review
- MDMA-assisted brief cognitive behavioral conjoint therapy for PTSD: Study protocol for a pilot study.Contemporary clinical trials communications · 2024Article
- Licit use of illicit drugs for treating depression: the pill and the process.The Journal of clinical investigation · 2024Review
- Article
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors' ongoing study exploring the potential role for MDMA-assisted psychotherapy to treat alcohol use disorder. MDMA therapy for PTSD is now entering the final Phase 3 stage of drug development, with a target set for licensing by the FDA and EMA in 2021. This means that if clinical efficacy criteria are achieved, MDMA would become a medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.